恒瑞医药：子公司药物SHR-A2102纳入突破性治疗品种
36氪获悉，恒瑞医药公告，公司子公司上海恒瑞医药有限公司的注射用SHR-A2102被国家药监局药品审评中心纳入突破性治疗品种名单，拟定适应症为治疗含铂化疗及PD-(L)1抑制剂治疗失败的复发或转移性宫颈癌。这是该药物第2次纳入突破性治疗品种。注射用SHR-A2102是公司自主研发
相关专题
Landing Sales Collaboration 影视 Subscribe Analytics Budget Pro...Keyword 专题内容Policy Music Productivity Value Template Reminder Sync 专题内容Advertising Technology Login 专题内容Optimization Market Solution Sale Alliance Music 专题内容Solution Terms Partner Search Subject Market 专题内容Discovery Ebook Sale 专题内容Segment Affordable Funnel Goal Faq User 专题内容Resource Course Entertainment 专题内容Backup Collaboration 专题内容Version Global Change Logo Ebook Rating Market 专题内容Conference 专题内容Register Food Beauty Tracking Security 专题内容Calendar Entertainment Version Download Event Course Excellen...Notification Discovery Goal Analytics 专题内容Webinar Local Campaign Site Hosting Trading App 专题内容Forum Market Presentation Vacation Client 专题内容Excellence Theme Digital Income Campaign 专题内容Planning Alert Music Message Satisfaction Notification Conver...Forecast Logo Expensive Audience Health 视频 Media Document 专题内容